New Free-to-Access 2-Hour Accredited Course 
Spot the Early Signs of Metachromatic Leukodystrophy (MLD)
Earn 2 EACCME Credits Today 

The online course is accredited by the European Accreditation Council for Continuing Medical Education (EACCME). The credits for the users of the course are 1 European CME credit (ECMEC®) for every hour (60 minutes of actual e-learning excluding introductions etc.) of use, provided that the users have completed a module and have passed the relevant assessment.

EIP is delighted to announce that a NEW accredited free-to-access training on Spotting the Signs of Metachromatic Leukodystrophy (MLD) has been added to the Online Academy Training Platform. We encourage you to take the training and share the registration link, below, with your colleagues and networks. All those who successfully complete the training (and pass the 3 short tests with a mark of 80% or above) can claim 2 hours of EACCME credits and a certificate will be issued by EIP.


Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of fats called sulfatides. This causes the destruction of the protective fatty layer (myelin sheath) surrounding the nerves in both the central nervous system and the peripheral nervous system, ultimately affecting intellectual and motor function. Early-onset clinical manifestations are often overlooked or confused with other conditions causing confusion among non-trained HCPs at first contact, resulting in misdiagnosis, wrong referral routes and delays in the early start of treatment. Delays in starting treatment have significant consequences on the conditions’ development and the patient’s health and quality of life. This delay in referral and treatment must be overcome. The 2-hours course covers the basics of MLD, practical neurological case studies that offer the opportunity to connect the theory with the practice and treatment options.

  • Understand the key signs and early symptoms of MLD in Children - with a knowledge of the hereditary causes, disease characteristics and what should trigger a referral
  • Identify the main neurological presenting sign and understand the impact of delays on the start of treatment on the condition’s development
  • Understand the main misdiagnosis and wrong referral routes for early-onset MLD in children
  • Have a comprehensive overview of the effective clinical management and established and emerging treatments for children with MLD

The Course consists of 3 lessons featuring videos of recorded lectures, further readings and assessments.
Click Here for Further Information and FREE Enrolment
Don’t Miss the Latest Practical Advice on the
Diagnosis of Mucopolysaccharidosis (MPS)

Check Out the MPS Resource Centre with 29 Free-to-View Recorded Webinars 

EIP has launched this dedicated Spot the Early Signs Resource Centre to spread education in local medical communities, and further develop and expand the trained on MPS frontline healthcare professionals network. All 29 recorded webinars are available to view without charge via the Resources Section of the site, along with further information on the Faculty, Campaigns and how you can Join Us to make your colleagues ‘think rare’ at every opportunity. The Resource Centre allows members to collaborate, engage and interact and where they can easily find information and education when needed - both for members and to share with colleagues.

Help us understand your needs and shape our future education programs. Take the short surveys below to share your views. Each survey consists of 9 questions and it will take no more than 3 minutes to complete each. 

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)







Plus, it's not too late to make your voice heard and suggest alternative disease topics to those listed above for EIP to consider developing a Spot the Early Signs Program. Use the link below to suggest new topics.

Suggest an Alternative SES Topic Here
The Spot The Early Signs program aims to fight under-diagnosed or late-diagnosed conditions for which treatments are available and where early detection and early treatment could make a significant difference in the condition's development, the quality of life and the survival of patients. 

The Spot The Early Signs Program is independently developed and managed by EiP in terms of content, topics and speakers appointed. Unrestricted grants are sought to support EIP activities. Sanofi Genzyme and Orchard Therapeutics, among other organisations, have provided unrestricted educational grants to partially support EIP's work on the misdiagnosis of rare diseases.
Share Share
Tweet Tweet
Forward Forward
Copyright © *|CURRENT_YEAR|*, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.